Clinical trial · no report yet · Phase 2
NADIMII
NADIM II: Neo-Adjuvant Immunotherapy
- NCT03838159 ↗
- Active, not recruiting
- Fundación GECP
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Paclitaxel; Carboplatin; Nivolumab
- Arms
- Experimental: Neo-Adjuvant Immunotherapy · Experimental
- Control: Neo-Adjuvant Chemotherapy · Active comparator
- Enrollment
- 90
- Primary outcomes
- Evaluation of the pathological complete response (pCR)
- Sponsor
- Fundación GECP
- Start
- May 15, 2019
- Primary completion
- Nov 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03838159 · updated Apr 30, 2026
Publications
linked from the registry- Sierra-Rodero B, Gil-Gonzalez A, Molina-Alejandre M, Nadal E, Calvo V, Lazaro M, Insa A, Massuti B, Martinez Marti A, de Castro J, Garcia Campelo R, Gonzalez Larriba JL, Bernabe R, Domine M, Ponce Aix S, Cobo M, Camps C, Reguart N, Bosch-Barrera J, Majem M, Aguilar A, Palmero R, Blanco Clemente M, Martin-Lopez J, Munoz-Viana R, Megias D, Gutierrez-Escobedo JM, Martinez-Toledo C, Cruz-Bermudez A, Provencio M. Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer. Clin Cancer Res. 2026 Apr 15;32(8):1499-1512. doi: 10.1158/1078-0432.CCR-25-3315. PubMed 41805895
- Provencio M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, Bernabe R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, Lopez Vivanco G, Camps C, Lopez-Castro R, Moran T, Barneto I, Rodriguez-Abreu D, Serna-Blasco R, Benitez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martin-Lopez J, Cruz-Bermudez A, Massuti B, Romero A. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. PubMed 37379158